361 related articles for article (PubMed ID: 25982111)
1. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).
Seliger SL; de Lemos J; Neeland IJ; Christenson R; Gottdiener J; Drazner MH; Berry J; Sorkin J; deFilippi C
JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.
Neeland IJ; Drazner MH; Berry JD; Ayers CR; deFilippi C; Seliger SL; Nambi V; McGuire DK; Omland T; de Lemos JA
J Am Coll Cardiol; 2013 Jan; 61(2):187-95. PubMed ID: 23219305
[TBL] [Abstract][Full Text] [Related]
3. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk.
Glick D; deFilippi CR; Christenson R; Gottdiener JS; Seliger SL
JACC Heart Fail; 2013 Aug; 1(4):353-360. PubMed ID: 24621939
[TBL] [Abstract][Full Text] [Related]
4. "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis).
Peters MN; Seliger SL; Christenson RH; Hong-Zohlman SN; Daniels LB; Lima JAC; de Lemos JA; Neeland IJ; deFilippi CR
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437599
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
Januzzi JL; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Verma S; Vedin O; Iwata T; Brueckmann M; Packer M; Anker SD;
JACC Heart Fail; 2022 Jul; 10(7):512-524. PubMed ID: 35670067
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study.
Berge K; Lyngbakken MN; Myhre PL; Brynildsen J; Røysland R; Strand H; Christensen G; Høiseth AD; Omland T; Røsjø H
Clin Biochem; 2021 Feb; 88():30-36. PubMed ID: 33245872
[TBL] [Abstract][Full Text] [Related]
7. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
8. N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure.
Zelt JGE; Liu PP; Erthal F; deKemp RA; Wells G; O'Meara E; Garrard L; Beanlands RSB; Mielniczuk LM
Can J Cardiol; 2017 Nov; 33(11):1478-1488. PubMed ID: 28966019
[TBL] [Abstract][Full Text] [Related]
9. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
[TBL] [Abstract][Full Text] [Related]
10. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
12. Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study.
Lewis AA; Ayers CR; Selvin E; Neeland I; Ballantyne CM; Nambi V; Pandey A; Powell-Wiley TM; Drazner MH; Carnethon MR; Berry JD; Seliger SL; DeFilippi CR; de Lemos JA
Circulation; 2020 Mar; 141(12):957-967. PubMed ID: 31931608
[TBL] [Abstract][Full Text] [Related]
13. Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study.
Juraschek SP; Daya N; Appel LJ; Miller ER; Matsushita K; Michos ED; Windham BG; Ballantyne CM; Selvin E
J Am Geriatr Soc; 2019 Sep; 67(9):1795-1802. PubMed ID: 31493355
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study).
Puleo CW; Ayers CR; Garg S; Neeland IJ; Lewis AA; Pandey A; Drazner MH; de Lemos JA
Biomark Med; 2021 Nov; 15(16):1487-1498. PubMed ID: 34663078
[No Abstract] [Full Text] [Related]
15. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular ejection fraction assessment in older adults: an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death?
deFilippi CR; Christenson RH; Kop WJ; Gottdiener JS; Zhan M; Seliger SL
J Am Coll Cardiol; 2011 Sep; 58(14):1497-506. PubMed ID: 21939835
[TBL] [Abstract][Full Text] [Related]
17. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
18. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
Pareek M
Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial.
Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
[TBL] [Abstract][Full Text] [Related]
20. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
